Study Details

Join the LEADS Study Waitlist The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset Alzheimer's disease (EOAD). Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across two cohorts: (1) individuals with EOAD and (2) cognitively normal (CN) control participants. The primary objectives of the LEADS study are to: collect longitudinal assessments and biomarker data; to compare baseline and longitudinal cognitive and functional characteristics between cognitively impaired and cognitively normal individuals, and EOAD and Late Onset Alzheimer's Disease (LOAD) individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI); and to study the associations of longitudinal clinical and cognitive assessments with multimodal imaging and biofluid markers that capture different elements of the AD pathophysiological cascade. Eligibility Criteria Inclusion Criteria (Cognitively Impaired Cohort Only): Diagnosed with MCI due to AD or probable AD dementia Age between 40-64 years (inclusive) Must have a study partner (informant) who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, caregiver) who is generally aware of the participant's cognitive and functional performance Principal Investigator Grant, Ian Michael ClinicalTrials.gov IdentifierNCT03507257IRB number STU00207242 More Info Join our Registry Email Ryan, Caila Ann Phone +1 312 503 3787

Join the LEADS Study Waitlist

The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset Alzheimer's disease (EOAD). Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across two cohorts: (1) individuals with EOAD and (2) cognitively normal (CN) control participants.

The primary objectives of the LEADS study are to: collect longitudinal assessments and biomarker data; to compare baseline and longitudinal cognitive and functional characteristics between cognitively impaired and cognitively normal individuals, and EOAD and Late Onset Alzheimer's Disease (LOAD) individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI); and to study the associations of longitudinal clinical and cognitive assessments with multimodal imaging and biofluid markers that capture different elements of the AD pathophysiological cascade.

Eligibility Criteria

Inclusion Criteria (Cognitively Impaired Cohort Only):

Diagnosed with MCI due to AD or probable AD dementia
Age between 40-64 years (inclusive)
Must have a study partner (informant) who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, caregiver) who is generally aware of the participant's cognitive and functional performance

Principal Investigator

Grant, Ian Michael

ClinicalTrials.gov IdentifierNCT03507257IRB number STU00207242

More Info

Join our Registry

Email Ryan, Caila Ann Phone +1 312 503 3787